About US

About MediSieve

MediSieve spun-out from University College London in 2015 to develop and commercialise magnetic blood filtration. The company has raised a total of £2.1M in equity funding and won grants worth a total of over £2M from the Wellcome Trust, Innovate UK, NIHR i4i and the EU Horizon 2020 SME Instrument. With the ability to specifically and selectively remove disease causing agents from the blood, magnetic blood filtration has the potential to transform the treatment of blood borne diseases. The company’s initial targets include Sepsis, Leukaemia and Malaria. Located in the new Imperial College Translation and Innovation Hub in White City, the company is preparing for first in man trials in 2019.

Latest News

Bake Sale in support of the UK Sepsis Trust

Bake Sale in support of the UK Sepsis Trust
Created on 20-09-2019

MediSieve held a charity bake sale to support the UK Sepsis Trust on the World Sepsis Day. 
MediSieve shortlisted for 2019 Emerging Technologies Competition, run by the Royal Society of Chemistry

MediSieve shortlisted for 2019 Emerging Technologies Competition, run by the Royal Society of Chemistry
Created on 06-09-2019

MediSieve was shortlisted for the final round of 2019 Emerging Technology Competition, run by the R...